References
- Lonn E. M., Yusuf S., Jha P., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–2069
- The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–1435
- SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
- Garg R., Yusuf S. for the Collaborative Group of ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–1456
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1992; 327: 685–691
- Pfeffer M. A., Braunwald E., Moye L. A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infraction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669–77
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–828
- Kober L., Torp-Pedersen C., Carlsen J. E., et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676
- Flather M., Kober L., Pfeffer M. A., et al. Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE studies). American Heart Association 7thScientific Session. Circulation 1997; 96: 1–706
- ACE-inhibitor Myocardial Infarction Collaborative Group. Indications for ACE-inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202–2212
- The Sixth Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publications 1997; No 98–4080.
- Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462
- Giatras I., Lau J., Levey A. S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337–45
- Tatti P., Pahor M., Byington R. P., Di Mauro P., Guarisco R., Strollo F. Results of the fosinopril amiodipine cardiovascular events trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Circulation 1997; 96: 1–764, abstr 4286.
- Estacio R. O., Jeffers B. W., Hiatt W. R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52
- GLANT Study Group. A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. Hypertens Res 1995; 18: 235–244
- CAPPP Trial Results. Lancet 1998, (in press)
- Holman R., Turner R., Stratton I., et al, UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20
- Yusuf S., Pepine C. J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–1178
- Rutherford J. D., Pfeffer M. A., Moye L. A., et al, SAVE investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. Circulation 1994; 90: 1731–1738
- Gertstein H. C., Pogue Bosch J., et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE-inhibitor and Vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Diabetes Care 1996; 19: 1225–1228
- Chaturvedi N., Sjolie A. K., Stephenson J. M., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28–31